热门资讯> 正文
AC Immune报告1H结果
2026-08-05 19:44
- AC Immune press release (ACIU): 1H total revenues for the six months ended June 30, 2026 were CHF16.2 million compared with CHF2.3 million for the same period in 2025. The increase was due to the achievement of milestones following the amended Lilly agreement resulting in CHF11.0 million of revenue recognized, and efforts under the Takeda arrangements resulting in CHF5.2 million of revenue recognized.
- The Company had total cash resources of CHF75.4 million (CHF91.4 million as of December 31, 2025), composed of CHF27.8 million in cash and cash equivalents and CHF47.6 million in short-term financial assets. The Company’s cash resources are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments.
More on AC Immune
- AC Immune: Holding Into A Make-Or-Break H2 2026 Readout
- AC Immune CEO Andrea Pfeifer to retire after 23 years
- Seeking Alpha’s Quant Rating on AC Immune
- Historical earnings data for AC Immune
- Financial information for AC Immune
推荐文章
美股前瞻 | 比特币一度突破7.8万美元！加密货币概念股盘前齐升；存储需求强劲！美光CEO称“全力生产也跟不上需求”
银色债券2026今起认购！保底息率4.25厘，每手3年累计派息至少1,275港元
华盛早报 | 贝森特两日救市！美债回购规模或超40亿美元；Anthropic冲击史上最大IPO；恒指季检结果，中际旭创、长飞光纤财报今日公布
美股前瞻 | 史诗级“轧空”来袭！比特币升破7.2万美元；业绩股齐遇冷！沃尔玛盘前大跌逾6%，阿里、网易均跌近4%
一图看懂 | AI与云业务表现强劲！阿里Q1营收2690亿元，同比增9%略超预期；阿里云外部商业化收入加速增至45%
一图看懂 | 泡泡玛特上半年营收171亿、净利50亿均大逊预期！星星人IP逆势暴涨580%；王宁称计划半年内大额回购20-50亿
Moderna暴涨177%！mRNA癌症疫苗迎来“ChatGPT时刻”？16只港美标的谁会接过下一棒？
“影子股”已暴涨90%！如何在Anthropic史上最大IPO前抢跑入局？最全攻略来了
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
